What ApoB actually is
Apolipoprotein B (ApoB) is a structural protein. Every atherogenic lipoprotein particle, LDL, VLDL, IDL, Lp(a), chylomicron remnants, carries exactly one ApoB molecule on its surface. Measure ApoB and you've directly counted the number of these particles in circulation.
This matters because cardiovascular disease is driven by particles, not by cholesterol. Each atherogenic particle has a chance of penetrating the arterial wall and depositing its cargo there over time. The more particles in circulation, the more chances of deposit. The cholesterol the particles carry is the cargo, not the mechanism.
LDL cholesterol, what you see on a standard lipid panel, measures the cholesterol mass inside LDL particles. Two people can have the same LDL-C with very different particle counts. The one with more particles (more ApoB) has higher risk despite identical LDL-C.
Why ApoB beats LDL as a risk predictor
The Sniderman et al. analyses and the recent UK Biobank work confirmed: when ApoB and LDL-C disagree, ApoB tracks cardiovascular events more accurately. The 2022 INTERHEART/PURE meta-analyses specifically showed ApoB outperformed both LDL-C and non-HDL cholesterol in predicting myocardial infarction across 50+ countries.
The Mendelian randomization studies, which use genetic variation to study causality, have repeatedly shown that genetic variants affecting ApoB cause cardiovascular events. The relationship is causal, not just correlational.
When LDL and ApoB disagree
About 20-30% of patients have "discordant" lipid profiles where LDL-C and ApoB give different risk pictures. The most common patterns:
- Normal LDL, high ApoB: small dense LDL particles. LDL-C appears reassuring while particle count is high. Common in metabolic syndrome, insulin resistance.
- High LDL, normal ApoB: large fluffy LDL particles. LDL-C looks bad while actual particle count is acceptable. Less concerning than the number suggests.
- Both high: straightforward elevated risk.
- Both low: low risk on this axis.
The discordant patient, high ApoB, normal LDL, is the one current standard care misses entirely. Their physician sees "normal cholesterol" and reassures them, while their actual particle burden is high.
Optimal ApoB ranges
| Patient context | Optimal ApoB (mg/dL) |
|---|---|
| General prevention (no CV disease) | <80 |
| Family history of CV disease | <70 |
| Diabetes or established CV disease | <60 |
| Aggressive longevity protocol | <60-65 |
Standard lab "normal" ranges go up to 130 mg/dL, well into the elevated-risk territory. Optimal is meaningfully tighter, like most lab ranges (see optimal vs normal lab ranges).
Current guideline support
ApoB has been progressively elevated in major guidelines:
- European Society of Cardiology (2019): ApoB recommended as alternative to LDL-C for risk assessment, particularly in patients with high triglycerides, diabetes, obesity, or metabolic syndrome.
- National Lipid Association (2014, updated): ApoB as supplementary marker, especially in discordant cases.
- Canadian Cardiovascular Society (2021): ApoB as primary marker in high-risk patients.
- Many longevity-oriented and progressive cardiology practices: ApoB as primary marker for everyone.
The science is settled. Clinical adoption lags as it usually does, typically 5-10 years behind evidence in U.S. primary care.
How to lower ApoB
The interventions that lower ApoB:
- Reduce visceral fat, drives ApoB lower meaningfully
- Reduce refined carbohydrate intake, lowers triglycerides and small-particle LDL production
- Reduce alcohol, alcohol raises triglycerides and ApoB
- Increase soluble fiber, 25+ g daily lowers LDL and ApoB
- Resistance training and cardio, both lower ApoB independent of weight
- Mediterranean diet, the PREDIMED trial showed ApoB reduction
- Statins, reduce ApoB 30-55% depending on dose and statin
- PCSK9 inhibitors, most powerful pharmaceutical option, 50-60% reduction
- Berberine, bempedoic acid, adjunct options for some patients
For weight-related ApoB elevation, tirzepatide and semaglutide often produce 15-25% ApoB reductions as a side benefit of the weight loss.
The statin question
Statins remain the most-evidenced cardiovascular drugs in history. The "statin debate" has been largely resolved at the population level, they prevent events. The individual decision still involves age, baseline risk, family history, and patient preference. ApoB is the right marker for monitoring statin response, the goal is not "LDL under 100" but ApoB at the target appropriate to your risk category.
Getting it tested
Most major labs run ApoB. Most insurance plans cover it. Quest Diagnostics test code: 31704. LabCorp: 167015. Comes with the standard fasting blood draw, no special preparation. Cost out-of-pocket is modest if insurance doesn't cover it.
OPTML's Optimized Health and Longevity panels include ApoB as standard. The Foundation panel can be upgraded to include it.
The clinical pearl: If you've ever been told your cholesterol is "normal" but you have visceral fat, family history of heart disease, or metabolic syndrome, get ApoB tested. The standard lipid panel can give a false sense of safety in these populations.
Bottom line
ApoB is the cardiovascular marker that should be ordered for almost everyone, and it isn't yet. The science settled this question years ago; clinical practice is catching up slowly. For preventive medicine and longevity-focused care, ApoB belongs on every panel. The discordant patients (high ApoB, normal LDL) are the ones most at risk of being missed by standard workups.